Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa Women's Health Study

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2226-2231

  Hayes, Jennifer H ^a   Anderson, Kristin E ^a   Folsom, Aaron R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; CORTISONE; EXCEDRIN; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PREDNISONE; SULINDAC;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIFESTYLE; LUNG CANCER; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; WOMEN'S HEALTH;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BODY MASS INDEX; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IOWA; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SMOKING; TIME FACTORS;

EID: 33845348197     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0172     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8.
3. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
4. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heathe CW, Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
5. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res 1988;48:4399-404.
6. Thun MJ. Aspirin and gastrointestinal cancer. Adv Exp Med Biol 1997;400A:395-402.
7. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
8. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933-7.
9. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001;33:682-7.
10. Johnson TW, Anderson KE, Lazovich D, Folsom A. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
11. Harris R, Kasbari S, Farrar W. Prospective study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol Rep 1999;6:71-3.
12. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999;82:473-6.
13. Anderson KE, Johnson TW, Lazovich D, Folsom A. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-71.
14. Jalbert G, Castonguay A. Effect of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992;66:21-8.
15. Castonguay A, Rioux N, Duperron C, Jalbert G. Inhibition of lung tumorigenesis by NSAIDs: a working hypothesis. Exp Lung Res 1998;24:605-15.
16. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002;23:1653-60.
17. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
18. Harris R, Namboodiri K, Farrar W. Epidemiologic study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1995;2:591-2.
19. Thompson HJ, Briggs S, Pasranka NS, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst (Bethesda) 1995;87:1259-60.
20. Vainio H, Morgan G. Cyclo-oxygenase 2 and breast cancer prevention. BMJ 1998;317:828-30.
21. Rioux N, Castonguay A. The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-κB. Carcinogenesis 2000;21:1745-51.
22. Kim HS, Song M, Kim E, Ryu SH, Suh P-G. Dexamethasone differentiates NG108-15 cells through cyclooxygenase 1 induction. Exp Mol Med 2003;35:203-10.
23. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
24. Peto R, Gray R, Collins R, Wheatley K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
25. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E. Aspirin use and lung cancer in men. Br J Cancer 2003;89:1705-8.
26. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
27. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
28. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002;9:693-5.
29. Muscat JE, Chen S, Richie JP, et al. Risk of lung carcinoma among users of nonsteroidal anti-inflammatory drugs. Cancer 2003;97:1732-6.
30. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995;24:107-9.
31. Langman MJS, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
32. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002;2:31.
33. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE. Aspirin and lung cancer in women. Br J Cancer 2002;87:49-53.
34. Cook NR, Lee I-M, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
35. Serenson HT, Friis S, Nørgård B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
36. Skriver MV, Nørgaard M, Poulson AH, et al. Use of nonaspirin NSAIDs and risk of lung cancer. Int J Cancer 2005;117:873-6.
37. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawke E. Aspirin use and mortality from cancer in a prospective study. Anticancer Res 2004;24:3177-84.
38. Ebbert JO, Yang P, Vachan CM, et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003;21:921-6.
39. Bisgard KM, Folsom AR, Hong CP, Sellers TA. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 1994;52:2447-55.
40. Folsom AR, Zhang S, Sellers TA, Zheng W, Kushi LH, Cerhan JR. Cancer incidence among women living on farms: findings from the Iowa Women's Health Study. J Occup Environ Med 1996;38:1171-6.
41. Willett WC, Sampson L, Stampfer MJ. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1986;124:17-27.
42. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003;106:784-8.
43. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. Available from: www.seer.cancer.gov.
44. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment, and survival. Population-based study of 20561 cases. Ann Oncol 2002;13:1087-93.
45. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990;8:1402-7.
46. IARC. Handbooks of cancer prevention I. Non-steroidal anti-inflammatory drugs. Lyon (France): IARC; 1997.